Holen Sie sich die Stockscreener-App
6.435
1.26%
0.095
Schlusskurs vom Vortag:
$6.34
Offen:
$6.33
24-Stunden-Volumen:
209.19K
Relative Volume:
0.21
Marktkapitalisierung:
$513.95M
Einnahmen:
$116.30M
Nettoeinkommen (Verlust:
$17.73M
KGV:
30.64
EPS:
0.21
Netto-Cashflow:
$20.88M
1W Leistung:
-2.43%
1M Leistung:
-7.36%
6M Leistung:
-53.75%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.29
$6.50
1-Wochen-Bereich:
$6.235
$6.77
52-Wochen-Spanne:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie NAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
6.44 | 505.97M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.22 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.08 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
872.32 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
390.98 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
202.11 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
Trade Recap: Is Niagen Bioscience Inc stock a smart buy before Fed meeting2025 Market Overview & Daily Market Momentum Tracking - moha.gov.vn
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How Niagen Bioscience Inc. (OCD1) stock reacts to fiscal policiesMarket Performance Report & Precise Buy Zone Tips - Newser
How Niagen Bioscience Inc. (OCD1) stock behaves under inflation pressureGold Moves & Low Risk High Reward Trade Ideas - Newser
A History of Outperforming Analyst Forecasts and Beating the Odds: Niagen Bioscience Inc (NAGE) - setenews.com
Can Niagen Bioscience Inc. (OCD1) stock sustain breakout momentumWeekly Trade Report & Capital Efficient Trading Techniques - Newser
Why Niagen Bioscience Inc. (OCD1) stock benefits from AI revolutionPortfolio Performance Report & Long-Term Growth Portfolio Plans - Newser
Is Niagen Bioscience Inc a good long term investmentTop Performing Stocks & Big Profit Small Budget - earlytimes.in
Taking the lead: Niagen Bioscience Inc (NAGE) - Setenews
A Look at Niagen Bioscience (NAGE) Valuation After New Skincare Launch and Long COVID Study Results - Sahm
How strong is Niagen Bioscience Inc. stock balance sheet2025 Market Trends & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
Niagen Bioscience (NAGE): Evaluating Valuation After Long COVID Study and Tru Niagen Beauty Launch - Yahoo Finance
Niagen Bioscience launches beauty supplement - Drug Store News
Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates - MSN
Will Niagen Bioscience Inc. (OCD1) stock justify high valuationWatch List & Stepwise Trade Signal Guides - newser.com
Is Niagen Bioscience Inc. stock a bargain at current levelsEarnings Recap Report & Low Risk High Win Rate Stock Picks - newser.com
Hope for Long-Covid Sufferers: Sponsored by Niagen Bioscience - KTLA
How Niagen Bioscience Inc. (OCD1) stock correlates with oil marketsPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Why Niagen Bioscience Inc. (OCD1) stock appears on watchlistsJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - newser.com
Is Niagen Bioscience Inc. stock a buy on dipsQuarterly Growth Report & High Accuracy Investment Entry Signals - newser.com
Best data tools to analyze Niagen Bioscience Inc. stockJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
How high can Niagen Bioscience Inc. stock goJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - newser.com
Is Niagen Bioscience Inc. stock undervalued vs historical averages - newser.com
Is Niagen Bioscience Inc. trending in predictive chart models2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Will Niagen Bioscience Inc. (OCD1) stock outperform value peersJuly 2025 Price Swings & Accurate Buy Signal Alerts - newser.com
Niagen Bioscience (NASDAQ:NAGE) CFO Acquires 4,465 Shares - MarketBeat
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Niagen Bioscience Inc-Aktie (NAGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
| Fried Robert N | Chief Executive Officer |
Apr 09 '25 |
Option Exercise |
3.30 |
66,667 |
220,001 |
1,038,981 |
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
0.12%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):